Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yang Min

Showing results (221-230 of 225) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 225 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2014
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutationGeoffrey Kim, Amy E McKee, Yang-Min Ning, et al.
The Oncologist|November 4, 2020
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate CancerMitchell S Anscher, Elaine Chang, Xin Gao, et al.
Imeta|May 8, 2026
Chromatin unwinding state for in situ identification and lineage tracing of circulating tumor cellsBin Ye, Zhen Wang, Yinqi Bai, et al.
BJU International|January 19, 2016
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Yang-Min Ning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2022
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor TherapyDaniel M Girardi, Scot A Niglio, Amir Mortazavi, et al.
Pageof 23

Showing results (221-230 of 225) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 225 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2014
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutationGeoffrey Kim, Amy E McKee, Yang-Min Ning, et al.
The Oncologist|November 4, 2020
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate CancerMitchell S Anscher, Elaine Chang, Xin Gao, et al.
Imeta|May 8, 2026
Chromatin unwinding state for in situ identification and lineage tracing of circulating tumor cellsBin Ye, Zhen Wang, Yinqi Bai, et al.
BJU International|January 19, 2016
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Yang-Min Ning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2022
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor TherapyDaniel M Girardi, Scot A Niglio, Amir Mortazavi, et al.
Pageof 23